VAL Share PerformanceMore
|52 week high||11.4900 04/10/16|
|52 week low||1.8700 27/06/17|
|52 week change||-5.0550 (-69.72%)|
|4 week volume||15,274,979 28/06/17|
Media for (VAL)
Latest News« previous» nextMore
22/06/2017 - 07:00 RNS
RNS Number: 8054I ValiRx PLC 22 June 2017 ValiRx Plc ("ValiRx" or the "Company") FORMATION OF & APPOINTMENTS TO AN ADVISORY BOARD London, UK ., 22 June 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to announce the formation of an Advisory Board ("AB") and that the following individuals have agre...
15/06/2017 - 07:00 RNS
RNS Number: 1252I ValiRx PLC 15 June 2017 ValiRx Plc ("ValiRx" or "the Company") ValiSeek Clinical Development Update Recruitment closes London, UK ., 15 June 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to provide an update on the clinical development of ValiSeek Limited ("ValiSeek"), the joint venture ("JV") between...
15/06/2017 - 00:00 BRR Media
01/06/2017 - 14:27 StockMarketWire
ValiRx has announced the conversion of the first tranche of the YA Global Master SPV Convertible Loan Facility (CLN). ...
01/06/2017 - 11:00 RNS
RNS Number: 8449G ValiRx PLC 01 June 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Yorkville CLN Conversion London, UK ., 1 June 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation an...
31/05/2017 - 11:00 RNS
RNS Number: 6961G ValiRx PLC 31 May 2017 Hardman Research: Developing novel cancer therapies Developing novel cancer therapies: ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company's two leading assets are in clinical trials:...
30/05/2017 - 15:01 StockMarketWire
ValiRx has announced that, at its Annual General Meeting held earlier today, all resolutions were passed. At 3:01pm: (LON:V...
30/05/2017 - 10:34 RNS
RNS Number: 5406G ValiRx PLC 30 May 2017 ValiRx Plc ("ValiRx" or the "Company") RESULT OF ANNUAL GENERAL MEETING London, UK ., 30 May 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. For more information, ple...
|Dividend yield||0 %|
Equity Research (VAL)
ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading...
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...
Latest discussion posts More
“Looks like he was right again. bet they miss him on the LSE board”▼
“Says news on Thursday will he be right again?”▼
“you have very interesting proposal for val, i wonder if u can contact me on advfn (same id) by sending a message i would like to invite you to join other LTH members who r on ...”▼
Codes & Symbols
|Symbols||VAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL|